19:11 , May 31, 2019 |  BC Extra  |  Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
19:37 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Proteomics company Seer launches with $36M

Counting nanoparticle pioneer Omid Farokhzad, Robert Langer and Biogen Inc. (NASDAQ:BIIB) vet Philip Ma among its founders, proteomic data company Seer Inc. (South San Francisco, Calif.) launched on Dec. 17 to develop liquid biopsy tests...
12:02 , Dec 17, 2018 |  BC Extra  |  Company News

Proteomics company Seer launches with $36M

Counting nanoparticle pioneer Omid Farokhzad, Robert Langer and Biogen Inc. (NASDAQ:BIIB) vet Philip Ma among its founders, proteomic data company Seer Inc. (South San Francisco, Calif.) launched Monday to develop liquid biopsy tests for early...
07:00 , Aug 16, 2016 |  BC Extra  |  Company News

Agios names Hirsch CFO

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) hired Andrew Hirsch as CFO, effective Sept. 19. SVP of Finance Glenn Goddard is to leave the cancer and metabolic company at the end of September. Hirsch was president and CEO...
07:00 , Aug 11, 2016 |  BC Innovations  |  Product R&D

Selecta spreads tolerance

Having been founded in 2008 to use its nanoparticles to stoke the immune system for vaccine applications, Selecta Biosciences Inc. is extending the platform with a 180˚ turn on that principle, using the same particles...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Company News

Bind Therapeutics, Pfizer deal

Bind selected a winning $40 million bid from Pfizer to acquire all of the biotech’s assets in a bankruptcy auction on July 25-26. A federal bankruptcy court approved the sale on July 27. Pfizer initially...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

Bind Therapeutics, Pfizer deal

Bind accepted a “stalking horse” bid from Pfizer to acquire substantially all of the biotech’s assets for $20 million in cash. Subject to bankruptcy court approval, and if Pfizer’s bid remains the highest and best...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Bind Therapeutics, Affilogic deal

Bind will investigate the use of Affilogic’s Nanofitins targeting immuno-oncology checkpoints as ligand components of Accurins. Bind’s Accurins are polymeric nanoparticle-encapsulated therapeutics engineered to target specific cells and tissues at the site of disease. The...
07:00 , May 2, 2016 |  BioCentury  |  Finance

Rational retail in Japan

The 2012 Japanese biotech bubble was fueled by irrational retail exuberance over a Nobel Prize awarded to a stem cell academic, but retail investors now are largely rewarding companies based on news events or upcoming...